ROSSI, Aroldo
 Distribuzione geografica
Continente #
NA - Nord America 970
EU - Europa 792
AS - Asia 94
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1858
Nazione #
US - Stati Uniti d'America 967
UA - Ucraina 279
SE - Svezia 181
IT - Italia 92
FI - Finlandia 56
RU - Federazione Russa 56
DE - Germania 55
VN - Vietnam 49
GB - Regno Unito 29
CN - Cina 28
FR - Francia 16
BE - Belgio 12
TR - Turchia 10
CH - Svizzera 6
PL - Polonia 6
UZ - Uzbekistan 5
CA - Canada 3
EU - Europa 2
LB - Libano 2
NL - Olanda 2
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1858
Città #
Chandler 261
Jacksonville 156
San Mateo 139
Ann Arbor 68
Medford 54
Princeton 54
Dong Ket 49
Altamura 44
Wilmington 38
Lawrence 32
Beijing 27
Perugia 26
Andover 23
Des Moines 21
Ashburn 20
Saint Petersburg 20
Woodbridge 15
Brussels 12
Boardman 11
Izmir 10
Norwalk 7
San Paolo di Civitate 7
Auburn Hills 5
Frankfurt Am Main 4
Los Angeles 4
Moscow 4
Marrùbiu 3
Ottawa 3
Philadelphia 3
Den Haag 2
Foligno 2
Helsinki 2
Redmond 2
San Diego 2
Bratislava 1
Centrale 1
Chicago 1
Fremont 1
Genova 1
Houston 1
Kiev 1
Modena 1
Nanning 1
Redwood City 1
San Giuliano Milanese 1
Stella Cilento 1
Terni 1
Totale 1143
Nome #
Botulinum toxin versus lidocaine in the treatment of myofacial pain: a double blind randomized study 80
A multidiscilinary method for a successful aging 74
Early detection of substantia nigra changes in Parkinson's disease: a magnetization transfer ratio (MTR) study 70
Skin biopsy: a new diagnostic tool for autonomic dysfunctions in Parkinson's disease? 68
Neurobiotica: studio multidisciplinare per il recupero delle funzioni cerebrali 61
Disturbi dell'equilibrio nei pazienti con cefalea primaria: entità reale o soggettiva? Valutazione qualitativa e quantitativa mediante stabilometria statica - Atti XVI Conresso Nazionale "Cefalee ed età della vita" 60
Tossina botulinica: nuove possibilità di impiego 55
Acute dystonia induced by the combination of midodrine and perphenazine. 53
Botulinum Toxin A Modulates Afferent Fibers in Neurogenic Detrusor Overactivity 52
Balance disorders in headache patients: evaluation by computerized static stabilometry 50
Clinical aspects and management of levodopa-induced dyskinesia. 50
A unique association of Marfan syndrome with craniofacial hypoplasia, oligophrenia and severe microphthalmia. 48
Validation of the Italian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. 44
Lysosomial hydrolase in cerebrospinal fluid from subjects with Parkinson's disease 42
Creatine kinase BB activity in serum of patients with acute stroke: correlation with the severity of brain damage. 41
Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson's disease. 41
A magnetization transfer study of mild and advanced Parkinson's disease. 40
Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. 38
Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. 37
Elevated beta-N-acetylhexosaminidase activity in focal dystonia fibroblasts 35
Demenza e pseudodemenza: utilità dei criteri diagnostici 35
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. 35
Botulinum A toxin modulates afferent fibers in neurogenic detrusor overactivity 34
Rapid effect of levetiracetam in a case of juvenile myoclonic epilepsy. 33
Rapid effect of levetiracetam in a case of juvenile myoclonic epilepsy 32
A young patient with type C multiple system atrophy and hereditary hemochromatosis. 32
Modificazioni del nervo sciatico nel ratto indotte da diete lipidiche. 31
Multimodal use of computed tomography in early acute stroke 30
Parkinsonism and cognitive impairment following chronic exposure to potassium cyanide. 30
Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. 30
Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients. 30
Hot water epilepsy and Mccune-Albright syndrome: a case report. 30
Botulinum Toxin A for Overactive Bladder and Detrusor Muscle Overactivity in Patients With Parkinson's Disease and Multiple System Atrophy 30
Botulinum A toxin intravesical injection in patients with Parkinson’ s disease and Multiple System Atrophy with overactive bladder syndrome and detrusor overactivity. 29
Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease 29
The endocannabinoid system in Parkinson's disease. 28
Occipital pseudoaneurysm as a complication of extension channel placement for DBS in Parkinson's disease. 28
The validity and reliability of the Italian Olfactory Identification Test (IOIT) in healthy subjects and in Parkinson's disease patients. 28
Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: results of a population-based study 26
Vomiting due to intravenous levetiracetam in a case of Creutzfeldt-Jakob disease. 26
Tappe dello sviluppo cerebrale in relazione alla disponibilità di nutrienti a partire dall'australopiteco 26
Shapiro's syndrome: Defining the clinical spectrum of the spontaneous paroxysmal hypothermia syndrome. 25
A novel spinocerebellar ataxia type 15 family with involuntary movements and cognitive decline 24
Il trattamento della sclerosi multipla 24
Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study 24
Elevated beta-N-acetylhexosaminidase activity in focal dystonia fibroblasts 23
The Brain Dopaminergic System and Hyperthermia: The Neuroleptic Malignant Syndrome and The Parkinsonism-hyperpyrexia Syndrome 21
Somministrazione intradetrusoriale di tossina botulinica A in pazienti con iperattività detrusoriale e vescica iperattiva dovute a M. di Parkinson ed atrofia multi- sistemica. 21
Disturbi dell'equilibrio in pazienti con mcefalea: diversi meccanismi patogenetici? 20
Role of Lysosomal Enzymes in Parkinson’s Disease: Lesson from Gaucher’s Disease 20
CSF Biomarkers in Parkinson's disease 20
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. 20
Complexity of motor sequences and cortical reorganization in Parkinson's disease: a functional MRI study. 17
Iodine- Iodine-123-N-omega-fluoropropyl fluoropropyl fluoropropyl-2beta-carbomethoxy carbomethoxy carbomethoxy-3beta-(4- iodophenyl)- iodophenyl)-nortropane nortropane nortropane brain SPET with brain SPET with brain SPET with semiquantitative analysis in semiquantitative analysis in Parkinson’s disease as evaluated by support vector machine classifier: diagnostic performance and influence of age diagnostic performance and influence of age 15
Totale 1945
Categoria #
all - tutte 4153
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4153


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201855 0000 00 033 15340
2018/201979 3250 141 72 04140
2019/2020248 76422 412 445 4627422
2020/2021551 5422245 14934 432 73215758
2021/2022436 13991228 141 2136 495266
2022/2023456 601501472 7185 40 0000
Totale 1945